Nasdaq to Delist CASI Pharmaceuticals Over Listing Compliance Failures
Key Facts
- •CASI Pharmaceuticals received a decision from the Nasdaq Hearings Panel to delist its securities from the exchange.
- •Trading of the company's securities on Nasdaq will be suspended at the open of business on February 26, 2026.
- •The delisting is due to the company's failure to satisfy Nasdaq's continued listing conditions.
CASI Pharmaceuticals has received a formal notification from the Nasdaq Hearings Panel regarding the decision to delist its securities from the exchange. The delisting decision stems from the company's failure to satisfy Nasdaq's continued listing requirements. Consequently, trading of the company's shares on the Nasdaq Stock Market will be suspended effective at the opening of business on February 26, 2026. This development marks a significant setback for the firm, as delisting typically results in a substantial loss of liquidity and diminished investor confidence. The removal from a major regulated exchange underscores the severe regulatory and financial hurdles the company has been unable to overcome. Investors are now bracing for the impact of this transition on the stock's valuation and future accessibility.
freemium.freemium.cta.signup
freemium.freemium.cta.signup_button